{"entity":{"id":"ab-205","kind":"drug","name":"AB-205","aka":["E-CEL cells"],"tldr":"AB-205 is an experimental allogeneic engineered endothelial cell therapy from Angiocrine Bioscience, in phase 3 trials for hodgkin lymphoma and non-Hodgkin lymphoma; its current status is not stated.","summary":"AB-205 (E-CEL cells) is an allogeneic engineered endothelial cell therapy (genetically engineered human umbilical vein endothelial cells) from Angiocrine Bioscience, with California Institute for Regenerative Medicine as partner. Infused engineered blood-vessel lining cells meant to prevent or reduce the severe organ complications of high-dose chemotherapy before an autologous stem cell transplant. Supportive care for people with lymphoma, not a treatment of the cancer itself. Its furthest stage is phase 3, for hodgkin lymphoma and non-Hodgkin lymphoma (patients undergoing high-dose therapy and autologous transplant). ClinicalTrials.gov registers it in 2 studies linked below. Phase 3 E-CELERATE NCT05181540 TERMINATED: registry reason 'Interim analysis showed lack of efficacy'. No company statement on the programme found. Whether it works in people has not been established unless a trial below reports it.","status":"phase-3","asOf":"2026-11-03","links":[{"label":"Angiocrine Bioscience: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT05181540"},{"label":"Angiocrine Bioscience: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT05181540"},{"label":"Angiocrine Bioscience: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT05181540"},{"label":"ClinicalTrials.gov: trials of AB-205","url":"https://clinicaltrials.gov/search?intr=AB-205"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["angiocrine-bioscience"],"institutions":[],"pathways":[],"terms":[],"trials":["nct05181540","nct03925935"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"AB-205","modality":"Allogeneic engineered endothelial cell therapy (genetically engineered human umbilical vein endothelial cells)","supportive":true,"mechanism":"Infused engineered blood-vessel lining cells meant to prevent or reduce the severe organ complications of high-dose chemotherapy before an autologous stem cell transplant. Supportive care for people with lymphoma, not a treatment of the cancer itself.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ab-205/","neighbours":{"cancer":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"company":[{"id":"angiocrine-bioscience","kind":"company","name":"Angiocrine Bioscience","route":"/companies/angiocrine-bioscience/"}],"trial":[{"id":"nct05181540","kind":"trial","name":"A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation","route":"/trials/nct05181540/"},{"id":"nct03925935","kind":"trial","name":"Trial of AB-205 in Adults With Lymphoma Undergoing High-Dose Therapy and Autologous Stem Cell Transplantation","route":"/trials/nct03925935/"}]}}